progabide
Sign in to saveAlso known as SL-76002, Gabren, Halogabide
Progabide, sold under the brand name Gabrene, is a GABA receptor agonist which is used in the treatment of epilepsy. It is an analogue of γ-aminobutyric acid (GABA) and acts both via a metabolite and as a prodrug of GABA, in turn behaving as an agonist of the GABA receptors.
Research
251 papers- Progabide: a new GABA-mimetic agent in clinical use.Clinical neuropharmacology · 1985
- Progabide for refractory partial epilepsy: a controlled add-on trial.Neurology · 1986
- Progabide, a GABA mimetic drug, stimulates the secretion of plasma corticosterone in rats.Pharmacology, biochemistry, and behavior · 1987
- In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide.Clinical pharmacology and therapeutics · 1993
- Comparison of progabide with other antiepileptic and GABAergic drugs.Epilepsia · 1985
via PubMed
~5 min read
Encyclopedic overview
12 sectionsContents
- Uses
- Side effects
- Pharmacology
- Chemistry
- Synthesis
- History
- Society and culture
- Names
- Availability
- Research
- See also
- References
Progabide, sold under the brand name Gabrene, is a GABA receptor agonist which is used in the treatment of epilepsy. It is an analogue of γ-aminobutyric acid (GABA) and acts both via a metabolite and as a prodrug of GABA, in turn behaving as an agonist of the GABA receptors.
==Uses== Progabide is approved in France for either monotherapy or adjunctive use in the treatment of epilepsy—specifically, generalized tonic–clonic, myoclonic, partial, and Lennox-Gastaut syndrome seizures—in both children and adults.
Excerpted from Wikipedia’s “progabide” article, available under the CC BY-SA 4.0 licence.